President Donald Trump plans to impose tariffs as high as 200% on imported generic medicines starting in 2028, aiming to reshore pharmaceutical production within the U.S. This policy could significantly impact global supply chains and the three major distributors that control most of the U.S. pharmaceutical market, potentially leading to higher drug prices or shortages if manufacturers cannot afford domestic production costs.
Read the full article at FreightWaves
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
3
Ali NematiWritten by Ali
